Xencor Set To Spruce Up Pfizer Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer gains wide access to test-drive antibody-enhancing tools via new licensing deal.
You may also be interested in...
J&J's Centocor To Develop Super Charged Antibodies Using Xencor's Technology
Under the licensing deal, Centocor has rights to use Xencor's XmAb and Xtend technologies to develop and commercialize and antibodies.
J&J's Centocor To Develop Super Charged Antibodies Using Xencor's Technology
Under the licensing deal, Centocor has rights to use Xencor's XmAb and Xtend technologies to develop and commercialize and antibodies.
Deals Of The Week: Merck Serono/Ambrx, Actelion/GeneraMedix...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.